The US Food and Drug Administration (FDA) has expanded the approval of GSK PLC (LSE:GSK, NYSE:GSK)’s Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer.
This includes patients with mismatch repair proficient or microsatellite stable tumours, which account for the majority of endometrial cancer cases.
The combination therapy of Jemperli and chemotherapy has shown a 31% reduction in the risk of death compared to chemotherapy alone.
The expanded approval is based on a supplemental biologics licence application (sBLA) that received a priority review. This approval allows more patients with limited treatment options to benefit from the therapy.